Celebrating the founding of Sanofi's future Evolutive Vaccines Facility (EVF) production unit (L-R): CEO Paul Hudson; Olivier Véran, Minister of Health; Frédérique Vidal, Minister of Higher Education, Research and Innovation; Jean Castex, Prime Minister; Agnès Pannier-Runacher, Minister of Industry; Eric Bellot, Mayor of Neuville-sur-Saône (courtesy Sanofi)
Sanofi CEO Paul Hudson sketches a $1B-plus investment on its new mRNA center
Over the years, Paris-based Sanofi has had a complex relationship with its home country of France. One former CEO (Chris Viehbacher) seemed to enjoy prodding the country’s R&D workforce for a lack of productivity — until the board chose a Frenchman (Olivier Brandicourt) to replace him. If only temporarily.
But CEO Paul Hudson, an urbane British executive with a global résumé, is making himself quite at home in the European country.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
